ARYA Atherosclerosis Journal

The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial

Document Type : Original Article(s)

Authors

Seyyed Mehdi Mirhashemi 1
Vajiheh Najafi 2
Fariba Raygan 3
Zatollah Asemi 2

1 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan AND Department of Clinical Biochemistry and Genetics, School of Medicine, Qazvin University of Medical Sciences, Qazvin Iran

2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

3 Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Abstract
BACKGROUND: Limited data are present that have assessed the effects of coenzyme Q10 (CoQ10) intake on cardiometabolic markers in type 2 diabetic patients with coronary heart disease (CHD). This study was done to determine the effects of CoQ10 administration on cardiometabolic markers in overweight diabetic patients with stable myocardial infarction. METHODS: This randomized double-blind placebo-controlled clinical trial was done among 60 diabetic patients with CHD aged 45-75 years old. Subjects were randomly allocated into two groups to receive either 100 mg/day CoQ10 supplements (n = 30) or placebo (n = 30) for 8 weeks. RESULTS: Compared with the placebo, CoQ10 intake led to a significant reduction in serum interleukin 6 (IL-6) (-1.7 ± 1.6 vs. 0.8 ± 1.7 ng/l, P < 0.001) and protein carbonyl (PCO) levels (-0.2 ± 0.3 vs. 0.1 ± 0.2 nmol/mg protein, P < 0.001). Supplementation with CoQ10 did not affect serum lipoprotein(a), advanced glycation end-products and thiol concentrations compared with the placebo. CONCLUSION: Overall, this study indicated that CoQ10 intake after 8 weeks among diabetic patients with the stable CHD had beneficial effects on serum IL-6 and PCO levels, but did not alter other cardiometabolic markers.  

Keywords

Coenzyme Q10
Supplementation
Cardiometabolic Markers
Type 2 Diabetes Mellitus
Coronary Heart Disease
  1. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the
  2. metabolic syndrome? Atheroscler Suppl 2005; 6(3): 11-4.
  3. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92(7): 785-92.
  4. Delbin MA, Trask AJ. The diabetic vasculature physiological mechanisms of dysfunction and influence of aerobic exercise training in animal models. Life Sci 2014; 102(1): 1-9.
  5. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49(23): 2231-7.
  6. Senes M, Erbay AR, Yilmaz FM, Topkaya BC, Zengi O, Dogan M, et al. Coenzyme Q10 and highsensitivity
  7. C-reactive protein in ischemic and idiopathic dilated cardiomyopathy. Clin Chem Lab Med 2008; 46(3): 382-6.
  8. Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit 2014; 20: 2183-8.
  9. Raygan F, Rezavandi Z, Dadkhah Tehrani S, Farrokhian A, Asemi Z. The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. Eur J Nutr 2015.
  10. Lee BJ, Tseng YF, Yen CH, Lin PT. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J 2013; 12(1): 142.
  11. Lee YJ, Cho WJ, Kim JK, Lee DC. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a doubleblind andomized controlled study. J Med Food 2011; 14(4): 386-90.
  12. Carmona MC, Lefebvre P, Lefebvre B, Galinier A, Benani A, Jeanson Y, et al. Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes (Lond) 2009; 33(2): 204-11.
  13. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Doring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 2008; 32(1-4): 179-83.
  14. Arroyo A, Kagan VE, Tyurin VA, Burgess JR, de Cabo R, Navas P, et al. NADH and NADPH-dependent reduction of coenzyme Q at the plasma membrane. Antioxid Redox Signal 2000; 2(2): 251-62.
  15. Gokbel H, Gergerlioglu HS, Okudan N, Gul I, Buyukbas S, Belviranli M. Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men. J Med Food 2010; 13(1): 216-8.
  16. Welles CC, Whooley MA, Karumanchi SA, Hod T, Thadhani R, Berg AH, et al. Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol 2014; 179(11): 1279-87.
  17. Abdollahzad H, Aghdashi MA, Asghari Jafarabadi M, Alipour B. Effects of coenzyme Q10 supplementation on inflammatory cytokines (TNFalpha, IL-6) and oxidative stress in rheumatoid arthritis patients: A randomized controlled trial. Arch Med Res 2015; 46(7): 527-33.
  18. Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T, Asemi Z. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, doubleblind, placebo-controlled trial. Clin Endocrinol (Oxf) 2015; 82(6): 885-91.
  19. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32(9 Suppl): S498-S504.
  20. Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials 2016; 13(2): 161-8.
  21. Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci 2015; 18(4): 169-76.
  22. Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, et al. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 2007; 62(4): 349-54.
  23. Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012; 28(7-8): 767-72.
  24. Starace D, Riccioli A, D'Alessio A, Giampietri C, Petrungaro S, Galli R, et al. Characterization of signaling pathways leading to Fas expression induced by TNF-alpha: pivotal role of NF-kappaB. FASEB J 2005; 19(3): 473-5.
  25. Yubero-Serrano EM, Delgado-Casado N, Delgado-Lista J, Perez-Martinez P, Tasset-Cuevas I, Santos-Gonzalez M, et al. Postprandial antioxidant effect of the Mediterranean diet supplemented with coenzyme Q10 in elderly men and women. Age (Dordr ) 2011; 33(4): 579-90.
  26. Juan YS, Hydery T, Mannikarottu A, Kogan B, Schuler C, Leggett RE, et al. Coenzyme Q10 protect against ischemia/reperfusion induced biochemical and functional changes in rabbit urinary bladder. Mol Cell Biochem 2008; 311(1-2): 73-80.
  27. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 2008; 14(2): 225-34.
  28. Okudan N, Nurullahoglu-Atalik KE, Revan S, Belviranli M, Balci SS, Gokbel H, et al. Effects of treatment with coenzyme Q10 on exercised rat aorta. Acta Physiol Hung 2012; 99(1): 40-50.
  29. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol 2008; 92(4): 548-51.
  30. Sarkar P, Kar K, Mondal MC, Chakraborty I, Kar M. Elevated level of carbonyl compounds correlates with insulin resistance in type 2 diabetes. Ann Acad Med Singapore 2010; 39(12): 909-4.
  31. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005; 31(6): 551-7.
ARYA Atherosclerosis Journal
Volume 12, Issue 4 - Serial Number 4
July and August 2016
Pages 158-165

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us